<DOC>
	<DOCNO>NCT01839604</DOCNO>
	<brief_summary>This phase I/Ib open-label , multicentre study ass safety , tolerability , pharmacokinetics preliminary anti-tumour activity AZD9150 patient advanced/metastatic hepatocellular carcinoma .</brief_summary>
	<brief_title>A Phase I/Ib Study AZD9150 ( ISIS-STAT3Rx ) Patients With Advanced/Metastatic Hepatocellular Carcinoma</brief_title>
	<detailed_description>A Phase I/Ib , Open-Label , Multicentre Study Assess Safety , Tolerability , Pharmacokinetics Preliminary Anti-tumour Activity AZD9150 Patients Advanced/Metastatic Hepatocellular Carcinoma .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Aged least 18 year . Patient Japan Taiwan age least 20 year Histologically cytologically confirm HCC ( exception fibrolamellar carcinoma mixed variant HCC fibrolamellar histology OR clinically diagnose HCC patient difficulty obtain histological diagnosis ) Relapsed , refractory , intolerant unlikely benefit sorafenib ( example due comorbidity ) Metastatic locally advance meeting ANY criterion : HCC suitable receive local therapy Disease recur refractory last therapy ( local systemic ) Eastern Cooperative Oncology Group ( ECOG ) performance status 01 deterioration previous 2 week minimum life expectancy 8 week More 2 prior systemic treatment HCC Prior grade 3 hematologic toxicity relate treatment JAK STAT3 inhibitor Presence hepatic encephalopathy within 4 week 1st dose Uncontrolled massive ascites High likelihood bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Child-Pugh A B7 ,</keyword>
	<keyword>Advanced/Metastatic Hepatocellular Carcinoma ,</keyword>
	<keyword>AZD9150 ,</keyword>
	<keyword>Antisense Oligonucleotide Inhibitor STAT3</keyword>
</DOC>